Video
Conference Coverage
Novel enfortumab vedotin induces responses in advanced urothelial cancers
CHICAGO – The investigational drug showed encouraging responses in patients with heavily pretreated locally advanced...
Conference Coverage
Laparoscopic surgery survival outcomes on par with open approach in colorectal liver metastases
CHICAGO – More centers should develop expertise in laparoscopic approach, investigator says.
Conference Coverage
ENZAMET trial: Early enzalutamide delays progression, improves survival in mHSPC
CHICAGO –Enzalutamide with standard first-line testosterone suppression delays progression and improves survival in...
Conference Coverage
Racial disparities in time to cancer care erased with Medicaid expansion
The gap in timely access to care between African Americans and whites diagnosed with advanced solid tumors disappeared with the Affordable Care...
Conference Coverage
Cleveland Clinic targets time to treat in cancer
CHICAGO – The Taussig Cancer Institute at the Cleveland Clinic reduced the time to treat for newly diagnosed cancer patients by 33%. Taussig’s...
Conference Coverage
Ribociclib plus endocrine therapy boosts survival of HR+/HER2- breast cancer
CHICAGO – The overall survival rate at 42 months was 70% in the combined therapy group, vs. 46% for patients treated...
Conference Coverage
In duodenal neuroendocrine tumors, resection technique matters
SAN DIEGO – Recurrence was less likely with a deeper resection technique.
Conference Coverage
Consider varying generational needs, preferences in the workplace and with patients
NASHVILLE, TENN. – Generational differences have important implications for communication, education, and more –...
Conference Coverage
Researchers propose new risk groups for NK-AML
NEWPORT BEACH, CALIF. – Investigators used machine learning algorithms to risk stratify patients with normal karyotype acute myeloid leukemia.
Conference Coverage
Combo proves most effective in HMA-naive, higher-risk MDS
NEWPORT BEACH, CALIF. – Oral rigosertib plus azacitidine produced a 90% response rate in higher-risk patients with myelodysplastic syndromes who...